Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase Ib dose finding and proof-of-concept trial of savolitinib in combination with durvalumab [MEDI-4736] as a second-line treatment in patients with clear renal cell carcinoma

Next Previous
Trial Profile

Phase Ib dose finding and proof-of-concept trial of savolitinib in combination with durvalumab [MEDI-4736] as a second-line treatment in patients with clear renal cell carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Savolitinib (Primary) ; Durvalumab
  • Indications Renal cell carcinoma
  • Focus Adverse reactions; Proof of concept

Most Recent Events

  • 02 Aug 2016 Status changed from planning to recruiting, according to a Chi-Med media release.
  • 15 Oct 2015 New trial record
  • 13 Oct 2015 According to a Chi-Med media release, this trial is expected to be initiated by the end of 2015.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top